Values as of: 2019-03-19
ETF | Mid-Cap Growth | NYSE Arca
Last Closing
USD 134.98Change
-0.19 (-0.14)%Market Cap
USD 0.52BVolume
0.01MAnalyst Target
N/A
N/A
Verdict
The investment seeks to track the performance of a benchmark index that measures the investment return of mid-capitalization growth stocks in the United States. The fund employs an indexing investment approach designed to track the performance of the S&P MidCap 400? Growth Index, which represents the growth companies, as determined by the index sponsor, of the S&P MidCap 400 Index. The Advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Company Website : www.vanguard.com
Currency: USD
Country : USA
Inception Date: 07/09/2010
Primary Benchmark: S&P MidCap 400 Growth TR USD
Primary Index: S&P 500 TR USD
Gross Expense Ratio: 0.2%
Management Expense Ratio: 0.20 %
N/A
N/A
| Symbol | Company Name | Allocation |
|---|---|---|
| TARS | Tarsus Pharmaceuticals Inc | 1.32 % |
N/A
N/A
| Symbol | Name | Mer | Price(Change) | Market Cap |
|---|---|---|---|---|
| VOT | Vanguard Mid-Cap Growth Index .. | 0.07 % |
-1.08 (-0.49%) |
USD 24.16B |
| IWP | iShares Russell Mid-Cap Growth.. | 0.24 % |
-0.52 (-0.49%) |
USD 14.98B |
| IJK | iShares S&P Mid-Cap 400 Growth.. | 0.24 % |
-0.31 (-0.36%) |
USD 9.44B |
| MDYG | SPDR® S&P 400 Mid Cap Growth .. | 0.15 % |
-0.31 (-0.38%) |
USD 3.06B |
| XMMO | Invesco S&P MidCap Momentum ET.. | 0.39 % |
-0.69 (-0.64%) |
USD 1.60B |
| RFG | Invesco S&P MidCap 400® Pure .. | 0.35 % |
-0.33 (-0.70%) |
USD 0.31B |
| IPO | Renaissance IPO ETF | 0.60 % |
-0.04 (-0.09%) |
USD 0.18B |
| ETHO | Etho Climate Leadership U.S. E.. | 0.45 % |
-0.11 (-0.20%) |
USD 0.18B |
| CWS | AdvisorShares Focused Equity E.. | 0.68 % |
-0.16 (-0.27%) |
USD 0.14B |
| BFOR | Barron's 400 ETF | 0.65 % |
-0.06 (-0.10%) |
USD 0.14B |
N/A
| Market Performance vs. Industry/Classification (Mid-Cap Growth) | Market Performance vs. Exchange (NYSE Arca) | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | 14.51% | 39% | F | 66% | D+ | ||
| Dividend Return | N/A | N/A | N/A | N/A | F | ||
| Total Return | 14.51% | 39% | F | 64% | D | ||
| Trailing 12 Months | |||||||
| Capital Gain | -2.04% | 47% | F | 48% | F | ||
| Dividend Return | 0.87% | 67% | D+ | 12% | F | ||
| Total Return | -1.17% | 41% | F | 41% | F | ||
| Trailing 5 Years | |||||||
| Capital Gain | 42.67% | 69% | C- | 79% | B- | ||
| Dividend Return | 5.72% | 62% | D | 18% | F | ||
| Total Return | 48.39% | 69% | C- | 73% | C | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | 9.45% | 71% | C- | 80% | B- | ||
| Dividend Return | 10.46% | 65% | D | 76% | C+ | ||
| Total Return | 1.01% | 71% | C- | 21% | F | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 9.97% | 76% | C+ | 67% | D+ | ||
| Risk Adjusted Return | 104.90% | 94% | A | 88% | B+ | ||
| Market Capitalization | 0.52B | 78% | C+ | 54% | F | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
There is nothing we particularly dislike
